Evidence map›Paper›PMID 29427202›Full record

ArticleJournal of cancer survivorship : research and practice2018

Predictors of vasomotor symptoms among breast cancer survivors.

Katherine W Reeves, Michael Pennell, Randi E Foraker, Carolyn J Crandall, Marcia Stefanick, Electra D Paskett

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Katherine W ReevesDepartment of Biostatistics and Epidemiology, University of Massachusetts, 411 Arnold House, 715 North Pleasant Street, Amherst, MA, 01003, USA. kwreeves@schoolph.umass.edu.
Michael PennellDivision of Biostatistics, College of Public Health, The Ohio State University, Columbus, OH, USA.
Randi E ForakerDivision of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH, USA.
Carolyn J CrandallDivision of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA.
Marcia StefanickStanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA, USA.
Electra D PaskettThe Division of Cancer Prevention and Control, Ohio State University, Columbus, OH, USA.
The Ohio State University · USStanford University · USUniversity of California, Los Angeles · USUniversity of Massachusetts Amherst · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
Women's Health Initiative Cancer Survivor CohortUM1CA173642 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ANDERSON, GARNET L., CAAN, BETTE J · 2013 to 2018
$12.1M
Life and Longevity After Cancer (LILAC): The Women's Health Initiative Cancer Survivor CohortU01CA173642 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ANDERSON, GARNET L., PASKETT, ELECTRA D. · 2019 to 2023
$7.5M
NCI NIH HHS P30 CA016058NCI NIH HHS U01 CA173642NCI NIH HHS UM1 CA173642NHLBI NIH HHS HHSN268201100046CNIA NIH HHS HHSN271201100004CWHI NIH HHS HHSN268201100001CWHI NIH HHS HHSN268201100002CWHI NIH HHS HHSN268201100004C
6 · The paper itself

Abstract

purposeVasomotor symptoms (VMS) are a common side effect of breast cancer treatment, yet modifiable factors that may predict VMS among breast cancer survivors are unknown.

methodsWe estimated multivariable-adjusted odds ratios and 95% confidence intervals (aOR, 95% CI) for predictors of VMS among 3595 breast cancer survivors enrolled in the Life and Longevity after Cancer (LILAC) study, an ancillary study of the Women's Health Initiative (WHI).

resultsVMS post-diagnosis were reported by 790 (22.0%) participants. Risk of VMS after diagnosis was positively associated with prior chemotherapy (aOR 1.80, 95% CI 1.21-2.68) and adjuvant hormone therapy (aOR 2.73, 95% CI 2.08-3.58), postmenopausal hormone therapy use (aOR 1.67, 95% CI 1.30-2.13), prior VMS (aOR 2.20, 95% CI 1.73-2.80), bilateral oophorectomy (aOR 1.77, 95% CI 1.37-2.27), and baseline antidepressant use (aOR 1.49, 1.06-2.09). VMS post-diagnosis were less likely among younger women (aOR 0.94, 95% CI 0.93-0.96), women younger at menopause (aOR 0.98, 95% CI 0.97-1.00), women with more time since diagnosis (aOR 0.92, 95% CI 0.90-0.94), and diabetics (aOR 0.45, 95% CI 0.21-0.95). Metabolic syndrome was not associated with post-diagnosis VMS (aOR 0.76, 95% CI 0.45-1.28).

conclusionsVMS following breast cancer diagnosis was related to a number of modifiable factors, but was unrelated to metabolic syndrome. IMPLICATIONS FOR CANCER SURVIVORS: Identification of factors that predispose women to VMS following a breast cancer diagnosis may allow clinicians to recognize and address VMS in the subset of women who are most likely to experience such symptoms.

Indexed as

Cancer SurvivorsVasomotor SystemAgedAntineoplastic AgentsBreast NeoplasmsDrug-Related Side Effects and Adverse ReactionsEstrogen Replacement TherapyFemaleHot FlashesHumansMenopauseMiddle AgedOvariectomyPrognosisRisk FactorsAntineoplastic AgentsBreast cancerMetabolic syndromeTreatmentVasomotor symptoms

Identifiers

PMID29427202
PMCPMC5955842
OpenAlexW2789711238

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.